Innoviva, Inc Stock News

Innoviva (INVA) priced its upsized offering of $225M principal amount of the 2.125% convertible senior notes due 2028; size of offering was increased from earlier announced…

Innoviva (INVA) trades 6.7% down premarket after it plans to offer $200M in principal amount of convertible senior notes due 2028 in a private offering to qualified…

Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Gainers: Dermata Therapeutics DRMA +35%. Innoviva (INVA) +11%. Mainz Biomed (MYNZ) +9%. Regional Health Properties RHE +9%. Envista Holdings (NVST) +8%.Losers: InfuSystem

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Announces Publication Of Positive Late-Stage Data For Keytruda-Chemo Combo In Breast Cancer Merc

Armata Pharmaceuticals Inc (NYSE: ARMP ) has received $45 million of equity investment from its largest shareholder, Innoviva Inc (NASDAQ: INVA ), following a $4.0 million investment in Q4 of 2021. Armata will use the proceeds to advance its clinical pipeline and strengthen its bacteriophage platform. AP-PA02 leads the pipeline, currently under evaluation in the ''SWARM-P.a.'' trial for chronic Pseudomonas aeruginosa infections in people with cystic fibrosis. A second study, ''diSArm,'' is evaluating AP-SA02 in patients with complicated Staphylococcus aureus … Full story available on Benzinga.com

Innoviva Reports Fourth Quarter 2021 Financial Results · Royalties increased by 18% to $111.1 million in the fourth | February 9, 2022

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today reported financial results for the fourth quarter and the year ended December 31, 2

Armata Pharmaceuticals (ARMP) will sell its shares and warrants to Innoviva Strategic Opportunities, a subsidiary of Innoviva (INVA) - Armata''s largest shareholder.The gross proceeds…

Entasis Therapeutics (ETTX) is trading ~15% higher in the pre-market after announcing that its existing investor, Innoviva submitted a non-binding proposal to buy the shares it

As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. The post 7 of the Top-Rated Pharmaceutical Stocks for Q1 appea

Virginia Retirement Systems ET AL reduced its holdings in shares of Innoviva, Inc. (NASDAQ:INVA) by 25.9% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 75,800 shares of the biotechnology companys stock after selling 26,500 shares during the period. Virginia Retirement Systems ET ALs holdings in Innoviva were worth $1,267,000 as of its most []

Equities research analysts predict that Innoviva, Inc. (NASDAQ:INVA) will announce $0.41 earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Innovivas earnings. Innoviva posted earnings per share of $0.48 in the same quarter last year, which would suggest a negative year-over-year growth rate of 14.6%. The business is []